Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer

10Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

The high mobility group A1 (HMGA1) protein is associated with poor prognosis in patients with a wide range of cancers. However, the affect of HMGA1 on the risk of mortality from breast cancer (BC) has not been fully characterized. In the present retrospective multiple center study, the HMGA1 expression level was determined by performing immunohistochemistry on surgical tissue samples of 273 BC specimens from the Second Affiliated Hospital of Zhejiang University (Zhejiang, China) and 310 BCs from the National Engineering Center for Biochip (Shanghai, China). Kaplan-Meier analysis and Cox proportional hazard model were employed to analyze the survivability. HMGA1 expression was significantly associated with tumor histological degree and body mass index (BMI). However, HMGA1 expression showed no prognostic value in patients with BC. Combined evaluation of HMGA1 expression and high BMI (≥24 kg/m2) predicted worse overall survival of BC. Therefore, HMGA1 and BMI were considered to serve synergistic roles in the development and progression of BC, and combined evaluation of HMGA1 expression and high BMI may be an effective marker in predicting poor prognosis of BC patients.

Cite

CITATION STYLE

APA

Zhang, S., Lei, R., Wu, J., Shan, J., Hu, Z., Chen, L., … Wang, X. (2017). Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer. Oncology Letters, 14(5), 5719–5726. https://doi.org/10.3892/ol.2017.6963

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free